Table 3.
Definitive antibiotics
| Variable | Total (N = 280) |
|---|---|
| Definitive antibiotic selection [n (%)] a | – |
| Beta-lactam | 209 (74.6) |
| Amoxicillin b | 69 (24.6) |
| Amoxicillin/clavulanate c | 11 (3.9) |
| Ampicillin | 1 (0.4) |
| Ampicillin/sulbactam | 2 (0.7) |
| Cefazolin d | 22 (7.9) |
| Cefdinir | 2 (0.7) |
| Cefepime | 2 (0.7) |
| Ceftriaxone e | 53 (18.9) |
| Cefuroxime | 3 (1.1) |
| Cephalexin f | 29 (10.4) |
| Ertapenem | 1 (0.4) |
| Penicillin G g | 10 (3.6) |
| Penicillin VK | 3 (1.1) |
| Piperacillin/tazobactam | 2 (0.7) |
| Non-beta-lactam | 38 (13.6) |
| Ciprofloxacin | 1 (0.4) |
| Clindamycin | 3 (1.1) |
| Daptomycin | 1 (0.4) |
| Doxycycline | 4 (1.4) |
| Levofloxacin | 4 (1.4) |
| Linezolid | 7 (2.5) |
| Metronidazole | 3 (1.1) |
| Trimethoprim/sulfamethoxazole | 5 (1.8) |
| Vancomycin | 12 (4.3) |
| No definitive antibiotic therapy | 45 (16.1) |
a
The sum of definitive antibiotics and patients that received no definitive antibiotic therapy here is 292, as 12 patients were prescribed both a beta-lactam and a non-beta-lactam.
b
Most frequent amoxicillin dose: 1 g PO TID (65.2%).
c
Most frequent amoxicillin/clavulanate dose: 875–125 mg PO BID (63.6%).
d
Most frequent cefazolin dose: 2 g IV Q8h (54.5%).
e
Most frequent ceftriaxone dose: 2 g IV Q24h (94.3%).
f
Most frequent cephalexin dose: 500 mg PO QID (55.2%).
g
Most frequent penicillin G dose: 24 million units IV Q24h via continuous infusion (90.0%).